Novavax Inc. has signed agreements with its partner, SK bioscience, for the manufacturing and supply of a version of the Novavax COVID-19 vaccine (NVX-CoV2373) containing Omicron variant and for the manufacture of the vaccine in prefilled syringes. The companies signed an agreement for the technology transfer of Novavax' proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants including the Omicron BA.5 subvariant. In addition, the companies have signed an agreement to manufacture and supply the Novavax COVID-19 vaccine in a prefilled syringe.

SK bioscience will begin work to enable the manufacturing process for commercial supply of the vaccine in prefilled syringes in 2023. Currently, SK bioscience manufactures drug substance for the vaccine. Novavax and SK bioscience also have a collaboration and licensing agreement under which SK bioscience exclusively commercializes the Novavax COVID-19 vaccine in South Korea, and with Novavax, jointly commercializes the vaccine in Vietnam and Thailand.